DOCSLIB.ORG

Meta-Analysis of 375,000 Individuals Identifies 38 Susceptibility Loci for Migraine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meta-Analysis of 375,000 Individuals Identifies 38 Susceptibility Loci for Migraine bioRxiv preprint doi: https://doi.org/10.1101/030288; this version posted November 3, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine Padhraig Gormley*,1,2,3,4, Verneri Anttila*,2,3,5, Bendik S Winsvold6,7,8, Priit Palta9, Tonu Esko2,10,11, Tune H. Pers2,11,78,79, Kai-How Farh2,5,12, Ester Cuenca-Leon1,2,3,13, Mikko Muona9,14,15,16, Nicholas A Furlotte17, Tobias Kurth18,19, Andres Ingason20, George McMahon21, Lannie Ligthart22, Gisela M Terwindt23, Mikko Kallela24, Tobias M Freilinger25,38, Caroline Ran26, Scott G Gordon27, Anine H Stam23, Stacy Steinberg20, Guntram Borck28, Markku Koiranen29, Lydia Quaye30, Hieab HH Adams31,81, Terho Lehtimäki60, Antti- Pekka Sarin9, Juho Wedenoja74, David A Hinds17, Julie E Buring19,33, Markus Schürks35, Paul M Ridker19,33, Maria Gudlaug Hrafnsdottir36, Hreinn Stefansson20, Susan M Ring21, Jouke-Jan Hottenga22, Brenda WJH Penninx37, Markus Färkkilä24, Ville Artto24, Mari Kaunisto9, Salli Vepsäläinen24, Rainer Malik25, Andrew C Heath39, Pamela A F Madden39, Nicholas G Martin27, Grant W Montgomery27, Eija Hämäläinen9, Hailiang Huang2,3,5, Andrea E Byrnes2,3,5, Lude Franke40, Jie Huang4, Evie Stergiakouli21, Phil H Lee1,2,3, Cynthia Sandor41, Caleb Webber41, Zameel Cader42,43, Bertram Muller-Myhsok44, Stefan Schreiber45, Thomas Meitinger46, Johan G Eriksson47,48, Veikko Salomaa48, Kauko Heikkilä32, Elizabeth Loehrer31,73, Andre G Uitterlinden50, Albert Hofman31, Cornelia M van Duijn31, Lynn Cherkas30, Linda M. Pedersen6, Audun Stubhaug51,52, Christopher S Nielsen51,53, Minna Männikkö29, Evelin Mihailov10, Lili Milani10, Hartmut Göbel55, Ann-Louise Esserlind56, Anne Francke Christensen56, Thomas Folkmann Hansen57, Thomas Werge75,76,77, Jaakko Kaprio9,58,59, Arpo J Aromaa48, Olli Raitakari61, M Arfan Ikram31,62,81, Tim Spector30, Marjo-Riitta Järvelin63,64,29,66, Andres Metspalu10, Christian Kubisch67, David P Strachan68, Michel D Ferrari23, Andrea C Belin26, Martin Dichgans25,69, Maija Wessman9,14, Arn MJM van den Maagdenberg23,80, John-Anker Zwart6,7,8, Dorret I Boomsma22, George Davey Smith21, Kari Stefansson20,70, Nicholas Eriksson17, Mark J Daly2,3,5, Benjamin M Neale**,2,3,5, Jes Olesen**,56, Daniel I. Chasman**,19,33, Dale R Nyholt**,71, and Aarno Palotie**,1,2,3,4,5,9,72 on behalf of the International Headache Genetics Consortium 1Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA. 2Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, USA. 3Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, USA. 4Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK. 5Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA. 6FORMI, Oslo University Hospital, P.O. 4956 Nydalen, 0424 Oslo, Norway. 7Department of Neurology, Oslo University Hospital, P.O. 4956 Nydalen, 0424 Oslo, Norway. 8Institute of Clinical Medicine, University of Oslo, P.O. 1171 Blindern, 0318 Oslo, Norway. 9Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. 10Estonian Genome Center, University of Tartu, Tartu, Estonia. 11Division of Endocrinology, Boston Children's Hospital, Boston, USA. 12Illumina, 5200 Illumina Way, San Diego, USA. 13Vall d'Hebron Research Institute, Pediatric Neurology, Barcelona, Spain. 14Folkhälsan Institute of Genetics, Helsinki, Finland, FI-00290. 15Neuroscience Center, University of Helsinki, Helsinki, Finland, FI- 00014. 16Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland, FI-00014. 1723andMe, Inc., 899 W. Evelyn Avenue, Mountain View, CA, USA. 18Inserm Research Center for Epidemiology and Biostatistics (U897), University of Bordeaux, 33076 Bordeaux, France. 19Division of Preventive Medicine, Brigham and Women's Hospital, Boston MA 02215. 20deCODE Genetics, 101 Reykjavik, Iceland. 21Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, UK. 22VU University Amsterdam, Department of Biological Psychology, Amsterdam, the Netherlands, 1081 BT. 23Leiden University Medical Centre, Department of Neurology, Leiden, The Netherlands, PO Box 9600, 2300 RC. 24Department of Neurology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland. 25Institute for Stroke and Dementia Research, Klinikum der Universtität München, Ludwig-Maximilians-Universität München, Feodor-Lynen-Str. 17, 1 bioRxiv preprint doi: https://doi.org/10.1101/030288; this version posted November 3, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 81377 Munich Germany. 26Karolinska Institutet, Department of Neuroscience, 171 77 Stockholm, Sweden. 27Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, QLD 4006, Australia. 28Ulm University, Institute of Human Genetics, 89081 Ulm, Germany. 29University of Oulu, Center for Life Course Epidemiology and Systems Medicine, Oulu, Finland, Box 5000, Fin-90014 University of Oulu. 30Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. 31Dept of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands, 3015 CN. 32Institute of Clinical Medicine, University of Helsinki, Helsinki, Finland. 33Harvard Medical School, Boston MA 02115. 35University Duisburg Essen, Essen, Germany. 36Landspitali University Hospital, 101 Reykjavik, Iceland. 37VU University Medical Centre, Department of Psychiatry, Amsterdam, the Netherlands, 1081 HL. 38Department of Neurology and Epileptology, Hertie Institute for Clincal Brain Research, University of Tuebingen. 39Department of Psychiatry, Washington University School of Medicine, 660 South Euclid, CB 8134, St. Louis, MO 63110, USA. 40University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 9700RB. 41MRC Functional Genomics Unit, Department of Physiology, Anatomy & Genetics, Oxford University, UK. 42Nuffield Department of Clinical Neuroscience, University of Oxford, UK. 43Oxford Headache Centre, John Radcliffe Hospital, Oxford, UK. 44Max-Planck-Institute of Psychiatry, Munich, Germany. 45Christian Albrechts University, Kiel, Germany. 46Institute of Human Genetics, Helmholtz Center Munich, Neuherberg, Germany. 47Department of General Practice and Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki Finland. 48National Institute for Health and Welfare, Helsinki, Finland. 50Dept of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands, 3015 CN. 51Dept of Pain Management and Research, Oslo University Hospital, Oslo, 0424 Oslo, Norway. 52Medical Faculty, University of Oslo, Oslo, 0318 Oslo, Norway. 53Division of Mental Health, Norwegian Institute of Public Health,P.O. Box 4404 Nydalen, Oslo, Norway, NO-0403. 55Kiel Pain and Headache Center, 24149 Kiel, Germany. 56Danish Headache Center, Department of Neurology, Rigshospitalet, Glostrup Hospital, University of Copenhagen, Denmark. 57Institute of Biological Psychiatry, Mental Health Center Sct. Hans, University of Copenhagen, Roskilde, Denmark. 58Department of Public Health, University of Helsinki, Helsinki, Finland. 59Department of Health, National Institute for Health and Welfare, Helsinki, Finland. 60Department of Clinical Chemistry, Fimlab Laboratories, and School of Medicine, University of Tampere, Tampere, Finland, 33520. 61Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku and the Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland, 20521. 62Dept of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands, 3015 CN. 63Imperial College London, Department of Epidemiology and Biostatistics, MRC Health Protection Agency (HPE) Centre for Environment and Health, School of Public Health, UK, W2 1PG. 64University of Oulu, Biocenter Oulu, Finland, Box 5000, Fin-90014 University of Oulu. 66Oulu University Hospital, Unit of Primary Care, Oulu, Finland, Box 10, Fin-90029 OYS. 67University Medical Center Hamburg Eppendorf, Institute of Human Genetics, 20246 Hamburg, Germany. 68Population Health Research Institute, St George's, University of London, Cranmer Terrace, London SW17 0RE, UK. 69Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 70Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland. 71Statistical and Genomic Epidemiology Laboratory, Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Kelvin Grove, QLD 4059, Australia. 72Department of Neurology, Massachusetts General Hospital, Boston, USA, 73Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, USA 02115. 74Department of Public Health, University of Helsinki, Helsinki, Finland. 75Institute Of Biological Psychiatry, MHC Sct. Hans, Mental Health Services Copenhagen, DK-2100 Copenhagen, Denmark. 76Institute of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Copenhagen, DK- 2100 Copenhagen, Denmark. 77iPSYCH - The Lundbeck Foundation's Initiative for Integrative Psychiatric Research, DK-2100
Load more

Recommended publications
  • Protein Interaction Network of Alternatively Spliced Isoforms from Brain Links Genetic Risk Factors for Autism
    ARTICLE Received 24 Aug 2013 | Accepted 14 Mar 2014 | Published 11 Apr 2014 DOI: 10.1038/ncomms4650 OPEN Protein interaction network of alternatively spliced isoforms from brain links genetic risk factors for autism Roser Corominas1,*, Xinping Yang2,3,*, Guan Ning Lin1,*, Shuli Kang1,*, Yun Shen2,3, Lila Ghamsari2,3,w, Martin Broly2,3, Maria Rodriguez2,3, Stanley Tam2,3, Shelly A. Trigg2,3,w, Changyu Fan2,3, Song Yi2,3, Murat Tasan4, Irma Lemmens5, Xingyan Kuang6, Nan Zhao6, Dheeraj Malhotra7, Jacob J. Michaelson7,w, Vladimir Vacic8, Michael A. Calderwood2,3, Frederick P. Roth2,3,4, Jan Tavernier5, Steve Horvath9, Kourosh Salehi-Ashtiani2,3,w, Dmitry Korkin6, Jonathan Sebat7, David E. Hill2,3, Tong Hao2,3, Marc Vidal2,3 & Lilia M. Iakoucheva1 Increased risk for autism spectrum disorders (ASD) is attributed to hundreds of genetic loci. The convergence of ASD variants have been investigated using various approaches, including protein interactions extracted from the published literature. However, these datasets are frequently incomplete, carry biases and are limited to interactions of a single splicing isoform, which may not be expressed in the disease-relevant tissue. Here we introduce a new interactome mapping approach by experimentally identifying interactions between brain-expressed alternatively spliced variants of ASD risk factors. The Autism Spliceform Interaction Network reveals that almost half of the detected interactions and about 30% of the newly identified interacting partners represent contribution from splicing variants, emphasizing the importance of isoform networks. Isoform interactions greatly contribute to establishing direct physical connections between proteins from the de novo autism CNVs. Our findings demonstrate the critical role of spliceform networks for translating genetic knowledge into a better understanding of human diseases.
    [Show full text]
  • ADAMTSL3 As a Candidate Gene for Schizophrenia: Gene Sequencing and Ultra-High Density Association Analysis by Imputation
    Schizophrenia Research 127 (2011) 28–34 Contents lists available at ScienceDirect Schizophrenia Research journal homepage: www.elsevier.com/locate/schres ADAMTSL3 as a candidate gene for schizophrenia: Gene sequencing and ultra-high density association analysis by imputation David J. Dow a, Julie Huxley-Jones b, Jamie M. Hall a, Clyde Francks b, Peter R. Maycox a, James N.C. Kew a, Israel S. Gloger a, Nalini A.L. Mehta a, Fiona M. Kelly a, Pierandrea Muglia b, Gerome Breen c, Sarah Jugurnauth c, Inti Pederoso c, David St.Clair d, Dan Rujescu e, Michael R. Barnes b,c,⁎ a Molecular Discovery Research, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park (North), Third Avenue, Harlow, CM19 5AW, UK b Computational Biology and Genetics, Quantitative Sciences, Drug Discovery, GlaxoSmithKline Pharmaceuticals, Gunnels Wood Road, Stevenage, SG1 2NY, UK c Division of Psychological Medicine and Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King's College, London, UK d Department of Mental Health, University of Aberdeen, Aberdeen, United Kingdom e Division of Molecular and Clinical Neurobiology, Department of Psychiatry, Ludwig-Maximilians-University, Munich, Germany article info abstract Article history: We previously reported an association with a putative functional variant in the ADAMTSL3 gene, just below Received 27 July 2010 genome-wide significance in a genome-wide association study of schizophrenia. As variants impacting the Received in revised form 29 November 2010 function of ADAMTSL3 (a disintegrin-like and metalloprotease domain with thrombospondin type I motifs- Accepted 11 December 2010 like-3) could illuminate a novel disease mechanism and a potentially specific target, we have used Available online 15 January 2011 complementary approaches to further evaluate the association.
    [Show full text]
  • The Role of Genetic Variation in Predisposition to Alcohol-Related Chronic Pancreatitis
    The Role of Genetic Variation in Predisposition to Alcohol-related Chronic Pancreatitis Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy by Marianne Lucy Johnstone April 2015 The Role of Genetic Variation in Predisposition to Alcohol-related Chronic Pancreatitis 2015 Abstract Background Chronic pancreatitis (CP) is a disease of fibrosis of the pancreas for which alcohol is the main causative agent. However, only a small proportion of alcoholics develop chronic pancreatitis. Genetic polymorphism may affect pancreatitis risk. Aim To determine the factors required to classify a chronic pancreatic population and identify genetic variations that may explain why only some alcoholics develop chronic pancreatitis. Methods The most appropriate method of diagnosing CP was assessed using a systematic review. Genetics of different populations of alcohol-related chronic pancreatitics (ACP) were explored using four different techniques: genome-wide association study (GWAS); custom arrays; PCR of variable nucleotide tandem repeats (VNTR) and next generation sequencing (NGS) of selected genes. Results EUS and sMR were identified as giving the overall best sensitivity and specificity for diagnosing CP. GWAS revealed two associations with CP (identified and replicated) at PRSS1-PRSS2_rs10273639 (OR 0.73, 95% CI 0.68-0.79) and X-linked CLDN2_rs12688220 (OR 1.39, 1.28-1.49) and the association was more pronounced in the ACP group (OR 0.56, 0.48-0.64)and OR 2.11, 1.84-2.42). The previously identified VNTR in CEL was shown to have a lower frequency of the normal repeat in ACP than alcoholic liver disease (ALD; OR 0.61, 0.41-0.93).
    [Show full text]
  • Plenary and Platform Abstracts
    American Society of Human Genetics 68th Annual Meeting PLENARY AND PLATFORM ABSTRACTS Abstract #'s Tuesday, October 16, 5:30-6:50 pm: 4. Featured Plenary Abstract Session I Hall C #1-#4 Wednesday, October 17, 9:00-10:00 am, Concurrent Platform Session A: 6. Variant Insights from Large Population Datasets Ballroom 20A #5-#8 7. GWAS in Combined Cancer Phenotypes Ballroom 20BC #9-#12 8. Genome-wide Epigenomics and Non-coding Variants Ballroom 20D #13-#16 9. Clonal Mosaicism in Cancer, Alzheimer's Disease, and Healthy Room 6A #17-#20 Tissue 10. Genetics of Behavioral Traits and Diseases Room 6B #21-#24 11. New Frontiers in Computational Genomics Room 6C #25-#28 12. Bone and Muscle: Identifying Causal Genes Room 6D #29-#32 13. Precision Medicine Initiatives: Outcomes and Lessons Learned Room 6E #33-#36 14. Environmental Exposures in Human Traits Room 6F #37-#40 Wednesday, October 17, 4:15-5:45 pm, Concurrent Platform Session B: 24. Variant Interpretation Practices and Resources Ballroom 20A #41-#46 25. Integrated Variant Analysis in Cancer Genomics Ballroom 20BC #47-#52 26. Gene Discovery and Functional Models of Neurological Disorders Ballroom 20D #53-#58 27. Whole Exome and Whole Genome Associations Room 6A #59-#64 28. Sequencing-based Diagnostics for Newborns and Infants Room 6B #65-#70 29. Omics Studies in Alzheimer's Disease Room 6C #71-#76 30. Cardiac, Valvular, and Vascular Disorders Room 6D #77-#82 31. Natural Selection and Human Phenotypes Room 6E #83-#88 32. Genetics of Cardiometabolic Traits Room 6F #89-#94 Wednesday, October 17, 6:00-7:00 pm, Concurrent Platform Session C: 33.
    [Show full text]
  • Systematic Data-Querying of Large Pediatric Biorepository Identifies Novel Ehlers-Danlos Syndrome Variant Akshatha Desai1, John J
    Desai et al. BMC Musculoskeletal Disorders (2016) 17:80 DOI 10.1186/s12891-016-0936-8 RESEARCH ARTICLE Open Access Systematic data-querying of large pediatric biorepository identifies novel Ehlers-Danlos Syndrome variant Akshatha Desai1, John J. Connolly1, Michael March1, Cuiping Hou1, Rosetta Chiavacci1, Cecilia Kim1, Gholson Lyon1, Dexter Hadley1 and Hakon Hakonarson1,2* Abstract Background: Ehlers Danlos Syndrome is a rare form of inherited connective tissue disorder, which primarily affects skin, joints, muscle, and blood cells. The current study aimed at finding the mutation that causing EDS type VII C also known as “Dermatosparaxis” in this family. Methods: Through systematic data querying of the electronic medical records (EMRs) of over 80,000 individuals, we recently identified an EDS family that indicate an autosomal dominant inheritance. The family was consented for genomic analysis of their de-identified data. After a negative screen for known mutations, we performed whole genome sequencing on the male proband, his affected father, and unaffected mother. We filtered the list of non- synonymous variants that are common between the affected individuals. Results: The analysis of non-synonymous variants lead to identifying a novel mutation in the ADAMTSL2 (p. Gly421Ser) gene in the affected individuals. Sanger sequencing confirmed the mutation. Conclusion: Our work is significant not only because it sheds new light on the pathophysiology of EDS for the affected family and the field at large, but also because it demonstrates the utility of unbiased large-scale clinical recruitment in deciphering the genetic etiology of rare mendelian diseases. With unbiased large-scale clinical recruitment we strive to sequence as many rare mendelian diseases as possible, and this work in EDS serves as a successful proof of concept to that effect.
    [Show full text]
  • High Expression of an Unknown Long Noncoding RNA RP11-290L1.3 from GDM Macrosomia and Its Effect on Preadipocyte Differentiation
    ID: 20-0584 10 2 Y Lin, Y Zhand, L Xu et al. RP11 enhanced preadipocyte 10:2 191–204 differentiation RESEARCH High expression of an unknown long noncoding RNA RP11-290L1.3 from GDM macrosomia and its effect on preadipocyte differentiation Yu Lin1,*, Yingying Zhang1,*, Lei Xu2,*, Wei Long1, Chunjian Shan1, Hongjuan Ding1, Lianghui You1, Chun Zhao1 and Zhonghua Shi1 1State Key Laboratory of Reproductive Medicine, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, People’s Republic of China 2Maternal and Child Health Care Hospital of Dongchangfu District, Liaocheng, People’s Republic of China Correspondence should be addressed to C Zhao or Z Shi: [email protected] or [email protected] *(Y Lin, Y Zhang and L Xu contributed equally to this work) Abstract Aims: Gestational diabetes mellitus (GDM)-induced macrosomia is predominantly Key Words characterized by fat accumulation, which is closely related to adipocyte differentiation. f long noncoding RNA An unknown long noncoding RNA RP11-290L1.3, referred to as RP11, was identified to f GDM be dramatically upregulated in the umbilical cord blood of women with GDM-induced f preadipocyte macrosomia in our previous study. We conducted this study to identify the function of differentiation RP11 in GDM-induced macrosomia. f macrosomia Methods: The effects of RP11 gain- and loss-of-function on HPA-v (human preadipocytes- f fat accumulation visceral) adipogenesis were determined with lentivirus mediated cell transduction. The mRNA and protein expression levels of adipogenesis makers were evaluated by qPCR/Western blot. Then, we performed the microarray and pathway analysis to explore the possible mechanisms by which RP11 regulates adipogenesis.
    [Show full text]
  • Potential Genes and Pathways Associated with Heterotopic
    Yang et al. Journal of Orthopaedic Surgery and Research (2021) 16:499 https://doi.org/10.1186/s13018-021-02658-1 RESEARCH ARTICLE Open Access Potential genes and pathways associated with heterotopic ossification derived from analyses of gene expression profiles Zhanyu Yang1,2, Delong Liu1,2, Rui Guan1, Xin Li1, Yiwei Wang1 and Bin Sheng1,2* Abstract Background: Heterotopic ossification (HO) represents pathological lesions that refer to the development of heterotopic bone in extraskeletal tissues around joints. This study investigates the genetic characteristics of bone marrow mesenchymal stem cells (BMSCs) from HO tissues and explores the potential pathways involved in this ailment. Methods: Gene expression profiles (GSE94683) were obtained from the Gene Expression Omnibus (GEO), including 9 normal specimens and 7 HO specimens, and differentially expressed genes (DEGs) were identified. Then, protein– protein interaction (PPI) networks and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed for further analysis. Results: In total, 275 DEGs were differentially expressed, of which 153 were upregulated and 122 were downregulated. In the biological process (BP) category, the majority of DEGs, including EFNB3, UNC5C, TMEFF2, PTH2, KIT, FGF13, and WISP3, were intensively enriched in aspects of cell signal transmission, including axon guidance, negative regulation of cell migration, peptidyl-tyrosine phosphorylation, and cell-cell signaling. Moreover, KEGG analysis indicated that the majority of DEGs, including EFNB3, UNC5C, FGF13, MAPK10, DDIT3, KIT, COL4A4, and DKK2, were primarily involved in the mitogen-activated protein kinase (MAPK) signaling pathway, Ras signaling pathway, phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) signaling pathway, and Wnt signaling pathway.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Regulation of Signaling and Metabolism by Lipin-Mediated Phosphatidic Acid Phosphohydrolase Activity
    biomolecules Review Regulation of Signaling and Metabolism by Lipin-mediated Phosphatidic Acid Phosphohydrolase Activity Andrew J. Lutkewitte and Brian N. Finck * Center for Human Nutrition, Division of Geriatrics and Nutritional Sciences, Department of Medicine, Washington University School of Medicine, Euclid Avenue, Campus Box 8031, St. Louis, MO 63110, USA; [email protected] * Correspondence: bfi[email protected]; Tel: +1-3143628963 Received: 4 September 2020; Accepted: 24 September 2020; Published: 29 September 2020 Abstract: Phosphatidic acid (PA) is a glycerophospholipid intermediate in the triglyceride synthesis pathway that has incredibly important structural functions as a component of cell membranes and dynamic effects on intracellular and intercellular signaling pathways. Although there are many pathways to synthesize and degrade PA, a family of PA phosphohydrolases (lipin family proteins) that generate diacylglycerol constitute the primary pathway for PA incorporation into triglycerides. Previously, it was believed that the pool of PA used to synthesize triglyceride was distinct, compartmentalized, and did not widely intersect with signaling pathways. However, we now know that modulating the activity of lipin 1 has profound effects on signaling in a variety of cell types. Indeed, in most tissues except adipose tissue, lipin-mediated PA phosphohydrolase activity is far from limiting for normal rates of triglyceride synthesis, but rather impacts critical signaling cascades that control cellular homeostasis. In this review, we will discuss how lipin-mediated control of PA concentrations regulates metabolism and signaling in mammalian organisms. Keywords: phosphatidic acid; diacylglycerol; lipin; signaling 1. Introduction Foundational work many decades ago by the laboratory of Dr. Eugene Kennedy defined the four sequential enzymatic steps by which three fatty acyl groups were esterified onto the glycerol-3-phosphate backbone to synthesize triglyceride [1].
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z
    REVIEW pubs.acs.org/CR The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z. Long* and Benjamin F. Cravatt* The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States CONTENTS 2.4. Other Phospholipases 6034 1. Introduction 6023 2.4.1. LIPG (Endothelial Lipase) 6034 2. Small-Molecule Hydrolases 6023 2.4.2. PLA1A (Phosphatidylserine-Specific 2.1. Intracellular Neutral Lipases 6023 PLA1) 6035 2.1.1. LIPE (Hormone-Sensitive Lipase) 6024 2.4.3. LIPH and LIPI (Phosphatidic Acid-Specific 2.1.2. PNPLA2 (Adipose Triglyceride Lipase) 6024 PLA1R and β) 6035 2.1.3. MGLL (Monoacylglycerol Lipase) 6025 2.4.4. PLB1 (Phospholipase B) 6035 2.1.4. DAGLA and DAGLB (Diacylglycerol Lipase 2.4.5. DDHD1 and DDHD2 (DDHD Domain R and β) 6026 Containing 1 and 2) 6035 2.1.5. CES3 (Carboxylesterase 3) 6026 2.4.6. ABHD4 (Alpha/Beta Hydrolase Domain 2.1.6. AADACL1 (Arylacetamide Deacetylase-like 1) 6026 Containing 4) 6036 2.1.7. ABHD6 (Alpha/Beta Hydrolase Domain 2.5. Small-Molecule Amidases 6036 Containing 6) 6027 2.5.1. FAAH and FAAH2 (Fatty Acid Amide 2.1.8. ABHD12 (Alpha/Beta Hydrolase Domain Hydrolase and FAAH2) 6036 Containing 12) 6027 2.5.2. AFMID (Arylformamidase) 6037 2.2. Extracellular Neutral Lipases 6027 2.6. Acyl-CoA Hydrolases 6037 2.2.1. PNLIP (Pancreatic Lipase) 6028 2.6.1. FASN (Fatty Acid Synthase) 6037 2.2.2. PNLIPRP1 and PNLIPR2 (Pancreatic 2.6.2.
    [Show full text]
  • Overexpression of Hormone-Sensitive Lipase Prevents Triglyceride Accumulation in Adipocytes
    Overexpression of hormone-sensitive lipase prevents triglyceride accumulation in adipocytes. C Sztalryd, … , M C Komaromy, F B Kraemer J Clin Invest. 1995;95(6):2652-2661. https://doi.org/10.1172/JCI117967. Research Article Hormone-sensitive lipase (HSL) is a cytosolic neutral lipase that hydrolyzes intracellular stores of triglycerides within adipocytes and is thought to be the rate limiting enzyme in lipolysis; however, direct evidence to prove this concept has been lacking. The present study was designed to establish the function of HSL in adipocytes. A 2360-bp fragment containing the entire HSL coding region was cloned into the vector pCEP4 and was used to transfect the 3T3-F442A adipogenic cell line. Nondifferentiated, transfected cells were screened for HSL overexpression by indirect immunofluorescence microscopy and confirmed by immunoblotting cell extracts with anti-HSL/fusion protein antibodies and by Northern blots for HSL mRNA. Stable transfectants overexpressing HSL were obtained and cloned. Compared with undifferentiated 3T3-F442A cells transfected with pCEP4 not containing the insert (vector alone) where HSL expression was very low, undifferentiated HSL transfectants had up to a 100-fold increase in HSL activity. Likewise, immunoreactive HSL protein and HSL mRNA levels were increased up to 100-fold in HSL transfectants. When confluent cells were allowed to differentiate by exposure to insulin, HSL expression increased in vector alone transfected cells, but remained below that observed in HSL transfectants. A similar degree of differentiation was seen in both vector alone and HSL transfectants when based on the induction of lipoprotein lipase. Cellular triglyceride content increased dramatically in the vector alone transfected cells […] Find the latest version: https://jci.me/117967/pdf Overexpression of Hormone-sensitive Lipase Prevents Triglyceride Accumulation in Adipocytes Carole Sztalryd, Michael C.
    [Show full text]